Published in AIDS Weekly, September 6th, 1999
"We have found a significant clue to explain why some HIV infected patients resist therapy even when they have no detectable levels of drug-resistant strains of the virus," said John Schuetz, PhD, St. Jude pharmaceutical sciences and principal investigator of the study.
Resistance to nucleoside drugs, which are the backbone of anti-HIV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.